Wellstar Urgent Care Crabapple

CLIA Laboratory Citation Details

2
Total Citations
7
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 11D2061013
Address 12460 Crabapple Road, Suite 901, Alpharetta, GA, 30004
City Alpharetta
State GA
Zip Code30004
Phone678 762-0574
Lab DirectorMIHAELA ILLE

Citation History (2 surveys)

Survey - December 17, 2025

Survey Type: Standard

Survey Event ID: NPQZ11

Deficiency Tags: D0000 D5807

Summary:

Summary Statement of Deficiencies D0000 A Clinical Laboratory Improvement Amendments (CLIA) initial survey was completed on December 17, 2025. The laboratory was not in compliance with applicable CLIA requirements found at 42 CFR 493.1 through 42 CFR 493.1780. The following deficiencies were cited: D5807 TEST REPORT CFR(s): 493.1291(d) (d) Pertinent "reference intervals" or "normal" values, as determined by the laboratory performing the tests, must be available to the authorized person who ordered the tests and, if applicable, the individual responsible for using the test results. This STANDARD is not met as evidenced by: Based on interview, document review, and laboratory policy review, the laboratory failed to ensure reference ranges for creatinine on a chemistry profile patient report were in agreement with the laboratory policy and/or manufacturer's instructions for use (IFU) for 6 (Patients #1 - #6) of 6 patient reports reviewed. Findings included: The manufacturer's IFU for the "iSTAT CHEM8+ Cartridge" revised 10/15/2021, indicated "Expected Values The reference range for whole blood are similar to reference ranges derived from serum or plasma measurements with standard laboratory methods." Per the manufacturer's IFU, "Crea [creatine] reference range 0.6 - 1.3 [milligram per deciliter (mg/dL)]." A laboratory policy titled, "Abbott iSTAT 1 System Chem8+ (Non-Waived)," published 07/16/2025, revealed, "Analytic Measurement Range, Notification Values and Reference Intervals: Crea [creatine] Female: 0.5 - 0.9 [mg/dL] Male: 0.7 - 1.2 [mg/dL]." Patients #1 - #6's chemistry profile revealed the reference range for creatinine as 0.44 - 1.03 mg/dL. During an interview on 12/17/2025 at 11:30 AM, the Laboratory Director confirmed the discrepant creatinine reference range values between the patients' chemistry profiles, Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- the laboratory policy, and the manufacturer's IFU for the Chem8+ test cartridge and was unable to explain the source of the creatinine reference range values as listed in the laboratory policy or on the patients' chemistry profiles provided and reviewed. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - November 24, 2025

Survey Type: Special

Survey Event ID: 0SVG11

Deficiency Tags: D0000 D2016 D2130 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 A proficiency testing desk review was completed on November 24, 2025. At the time of the review, the laboratory was not in compliance with the Clinical Laboratory Improvement Amendments of 1988, 42 CFR 493.1 through 42 CFR 493.1780. The following condition deficiencies were cited: D2016 - 42 CFR 493.803 Condition: Successful participation [proficiency testing] D6000 - 42 CFR 493.1403 Condition: Moderate Complex Laboratory Director D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the CASPER 155 report and review of the American Proficiency Institute (API) reports, the laboratory failed to maintain satisfactory proficiency Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- testing (PT) participation for hemaglobin (HGB) in 2025 events 1 & 3, resulting in an initial unsuccessful participation for HGB. Refer to D 2130 D2130 HEMATOLOGY CFR(s): 493.851(f) (f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the Centers for Medicare and Medicaid (CMS) CASPER 155 report and review of American Proficiency Institute (API) reports, the laboratory failed to maintain satisfactory participation in two of three testing events ( 2025 events 1 & 3), resulting in an initial unsuccessful participation for HGB. Findings: 1. A review of Casper Report 155 revealed the laboratory failed HGB on the following: 2025 Event 1 HGB Score 60% 2025 Event 3 HGB Score 60% 2. A review of the laboratory's API Reports confirmed the laboratory failed HGB with the aforementioned scores. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on review of the CMS CASPER 155 report and review of American Proficiency Institute (API) reports, the laboratory director failed to provide overall management and direction for proficiency testing performance. The laboratory director failed to ensure proficiency testing samples were tested as required. Refer to D6016 D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on review of the CMS CASPER Report 155 and the American Proficiency Institute (API) 2025 events 1 & 3 PT evaluation reports, the laboratory director failed to ensure successful proficiency testing performance in HGB in two of three testing events ( 2025 events 1 and 3), resulting in the initial unsuccessful participation for HGB. Findings: 1. A review of Casper Report 155 revealed the laboratory failed HGB on the following: 2025 Event 1 HGB Score 60% 2025 Event 3 HGB Score 60% 2. A review of the laboratory's API Reports confirmed the laboratory failed HGB with the aforementioned scores. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access